TGFB1 and neoplasm: The drug can effectively reduce the formation of cell matrix around the tumor tissue by targeting TGF-β and anti-PD-L1 to further promote the penetration of T cells into the center of the tumor and trigger a more effective anti-tumor immune effect [131–133].